Suppr超能文献

支链多胺对朊病毒的清除作用及其治疗意义。

Elimination of prions by branched polyamines and implications for therapeutics.

作者信息

Supattapone S, Nguyen H O, Cohen F E, Prusiner S B, Scott M R

机构信息

Institute for Neurodegenerative Diseases, University of California, San Francisco, CA 94143-0518, USA.

出版信息

Proc Natl Acad Sci U S A. 1999 Dec 7;96(25):14529-34. doi: 10.1073/pnas.96.25.14529.

Abstract

We report that branched polyamines, including polyamidoamide dendimers, polypropyleneimine, and polyethyleneimine, are able to purge PrP(Sc), the protease-resistant isoform of the prion protein, from scrapie-infected neuroblastoma (ScN2a) cells in culture. The removal of PrP(Sc) by these compounds depends on both the concentration of branched polymer and the duration of exposure. Chronic exposure of ScN2a cells to low noncytotoxic concentrations of branched polyamines for 1 wk reduced PrP(Sc) to an undetectable level, a condition that persisted at least 3 wk after removal of the compound. Structure-activity analysis revealed that a high surface density of primary amino groups is required for polyamines to eliminate PrP(Sc) effectively from cells. The removal of PrP(Sc) by branched polyamines is attenuated by chloroquine in living cells, and exposure of scrapie-infected brain extracts with branched polyamines at acidic pH rendered the PrP(Sc) susceptible to protease in vitro, suggesting that endosomes or lysozomes may be the site of action. Our studies suggest that branched polyamines might be useful therapeutic agents for treatment of prion diseases and perhaps a variety of other degenerative disorders.

摘要

我们报告称,包括聚酰胺-胺树状大分子、聚丙烯亚胺和聚乙烯亚胺在内的支链多胺能够从培养的羊瘙痒症感染的神经母细胞瘤(ScN2a)细胞中清除朊病毒蛋白的蛋白酶抗性异构体PrP(Sc)。这些化合物对PrP(Sc)的清除取决于支链聚合物的浓度和暴露持续时间。将ScN2a细胞长期暴露于低浓度的无细胞毒性的支链多胺中1周,可将PrP(Sc)降低至检测不到的水平,在去除该化合物后,这种情况至少持续3周。结构-活性分析表明,多胺要有效从细胞中消除PrP(Sc),需要高表面密度的伯氨基。在活细胞中氯喹会减弱支链多胺对PrP(Sc)的清除作用,并且在酸性pH条件下用支链多胺处理羊瘙痒症感染的脑提取物,可使PrP(Sc)在体外对蛋白酶敏感,这表明内体或溶酶体可能是作用位点。我们的研究表明,支链多胺可能是治疗朊病毒疾病以及或许多种其他退行性疾病的有用治疗剂。

相似文献

1
Elimination of prions by branched polyamines and implications for therapeutics.
Proc Natl Acad Sci U S A. 1999 Dec 7;96(25):14529-34. doi: 10.1073/pnas.96.25.14529.
2
Branched polyamines cure prion-infected neuroblastoma cells.
J Virol. 2001 Apr;75(7):3453-61. doi: 10.1128/JVI.75.7.3453-3461.2001.
6
Quiescin-sulfhydryl oxidase inhibits prion formation .
Aging (Albany NY). 2016 Dec 11;8(12):3419-3429. doi: 10.18632/aging.101132.
9
Synthesis of benzamide derivatives and their evaluation as antiprion agents.
Bioorg Med Chem. 2012 Aug 15;20(16):5001-11. doi: 10.1016/j.bmc.2012.06.026. Epub 2012 Jun 20.

引用本文的文献

1
Dendrimers and Derivatives as Multifunctional Nanotherapeutics for Alzheimer's Disease.
Pharmaceutics. 2023 Mar 24;15(4):1054. doi: 10.3390/pharmaceutics15041054.
2
Synthesis and anti-prion aggregation activity of acylthiosemicarbazide analogues.
J Enzyme Inhib Med Chem. 2023 Dec;38(1):2191164. doi: 10.1080/14756366.2023.2191164.
3
Prion therapeutics: Lessons from the past.
Prion. 2022 Dec;16(1):265-294. doi: 10.1080/19336896.2022.2153551.
4
Dendrimers as Antiamyloid Agents.
Pharmaceutics. 2022 Mar 31;14(4):760. doi: 10.3390/pharmaceutics14040760.
5
Cationic Carbosilane Dendrimers Prevent Abnormal α-Synuclein Accumulation in Parkinson's Disease Patient-Specific Dopamine Neurons.
Biomacromolecules. 2021 Nov 8;22(11):4582-4591. doi: 10.1021/acs.biomac.1c00884. Epub 2021 Oct 6.
6
Repurposing Chloroquine Against Multiple Diseases With Special Attention to SARS-CoV-2 and Associated Toxicity.
Front Pharmacol. 2021 Apr 12;12:576093. doi: 10.3389/fphar.2021.576093. eCollection 2021.
7
Human cerebral organoids as a therapeutic drug screening model for Creutzfeldt-Jakob disease.
Sci Rep. 2021 Mar 9;11(1):5165. doi: 10.1038/s41598-021-84689-6.
8
Dendrimers and Dendritic Materials: From Laboratory to Medical Practice in Infectious Diseases.
Pharmaceutics. 2020 Sep 14;12(9):874. doi: 10.3390/pharmaceutics12090874.
9
Inactivation of Scrapie Prions by the Electrically Charged Disinfectant CAC-717.
Pathogens. 2020 Jul 3;9(7):536. doi: 10.3390/pathogens9070536.
10

本文引用的文献

1
Deaths from variant Creutzfeldt-Jakob disease.
Lancet. 1999 Mar 20;353(9157):979. doi: 10.1016/s0140-6736(99)01160-5.
2
Translating cell biology into therapeutic advances in Alzheimer's disease.
Nature. 1999 Jun 24;399(6738 Suppl):A23-31. doi: 10.1038/399a023.
3
The cell biology of beta-amyloid precursor protein and presenilin in Alzheimer's disease.
Trends Cell Biol. 1998 Nov;8(11):447-53. doi: 10.1016/s0962-8924(98)01363-4.
4
Prions.
Proc Natl Acad Sci U S A. 1998 Nov 10;95(23):13363-83. doi: 10.1073/pnas.95.23.13363.
6
alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies.
Proc Natl Acad Sci U S A. 1998 May 26;95(11):6469-73. doi: 10.1073/pnas.95.11.6469.
7
Alzheimer's disease.
BMJ. 1998 Feb 7;316(7129):446-8. doi: 10.1136/bmj.316.7129.446.
8
Transmissions to mice indicate that 'new variant' CJD is caused by the BSE agent.
Nature. 1997 Oct 2;389(6650):498-501. doi: 10.1038/39057.
9
The same prion strain causes vCJD and BSE.
Nature. 1997 Oct 2;389(6650):448-50, 526. doi: 10.1038/38925.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验